Funding for this research was provided by:
National Human Genome Research Institute (UM1 HG008853, 5U54HG003079)
Sigrid Juséliuksen Säätiö
Academy of Finland (312062, 285380)
National Heart, Lung, and Blood Institute (T32HL007081)
National Center for Advancing Translational Sciences (UL1TR002345)
University of Helsinki HiLIFE
Received: 23 March 2021
Accepted: 26 May 2021
First Online: 7 June 2021
: All participants in both the METSIM and FINRISK studies provided informed consent, and study protocols were approved by the Ethics Committees at participating institutions (National Public Health Institute of Finland, Hospital District of Helsinki and Uusimaa, and Hospital District of Northern Savo). All relevant ethics committees approved this study.
: Not applicable
: NOS has received grant funding from Regeneron Pharmaceuticals for unrelated work. The rest of the authors declare no competing interests.